FAST NEWS: Henlius Biotech’s revenue doubles in first quarter
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported its revenue soared 97.2% to 996 million yuan ($145 million) in the first quarter, according to a business update released on Sunday.…
Recent Articles
RECENT ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Rebounding RLX plots course beyond China
RLX.US
-
Hesai zooms ahead in third quarter, setting stage for milestone year
HSAI.US
